Outpost Medicine Expands Senior Leadership Team
LEXINGTON, Mass. & LONDON–(BUSINESS WIRE)–Outpost Medicine, a biopharmaceutical company focused on the development
of new treatments of urologic and gynecologic diseases and disorders,
today announced additions to its senior leadership team, including:
-
Nancy Martin, M.D., Pharm.D., as Senior Vice President, Chief Medical
Officer - Gordon McMurray, Ph.D., as Chief Scientific Officer
- Gale Kennedy as Vice President, Clinical Development
- Mike Ramsay as Vice President, Manufacturing
“Following our recent $41 million Series A financing and licensing of
our lead product candidate, OP-233, from Takeda, we are very pleased to
announce the formation of the Outpost senior leadership team,” said
David Socks, Chief Executive Officer of Outpost. “Gale, Gordon, Mike,
and Nancy are proven leaders with deep urology and drug development
expertise ideally suited to accelerate the development of OP-233 and
grow Outpost into a leading urology and women’s health therapeutics
company.” OP-233 (formerly TAK-233) is a clinical-stage product
candidate in development for the treatment of stress urinary
incontinence.
Dr. Martin most recently served as Vice President, Clinical Development
Biosimilars at Pfizer, which she joined through the acquisition of
Hospira, where she substantially built out the clinical development
organization. Prior to Hospira, she spent six years with Astellas Pharma
in roles of increasing responsibility, most recently as Senior Medical
Director, Scientific and Medical Affairs, with a focus on the urology
therapeutic area. During her tenure at Astellas, Dr. Martin led the
clinical development of mirabegron through Phase II, III, and global
regulatory approvals for the treatment of overactive bladder. She also
led the medical affairs team through product launch. Previously, Dr.
Martin held roles in clinical pharmacology at Aventis and Hoffman-La
Roche. She earned her M.D. from the University of Medicine and Dentistry
of New Jersey and Pharm.D. from the University of Illinois at Chicago.
Dr. McMurray joined Outpost from Pfizer, where he was most recently Head
of Pharmacology for the Neuroscience and Pain Research Unit. He
previously served in multiple Research Project and Team Leader roles in
both the Pain and Sensory Disorders Research Unit and the Genitourinary
and Sexual Dysfunction Research Unit. During that time, Dr. McMurray led
multiple research programs targeting important urologic diseases and
conditions, including stress urinary incontinence, overactive bladder,
and interstitial cystitis. Prior to Pfizer, he was Lecturer in
Pharmacology and Laboratory Head in the Department of Pharmacology at
Oxford University, where he was a member of the Oxford Continence Group.
Dr. McMurray holds a B.Sc. and Ph.D. from Queen’s University Belfast.
Ms. Kennedy most recently served as Senior Director, Clinical Science at
Takeda. During that time, she had clinical leadership responsibilities
for multiple clinical-stage urology programs, including OP-233 (formerly
TAK-233). Prior to Takeda, Ms. Kennedy was Programme Director at
Plethora Solutions, where she led Phase III development for a sexual
dysfunction program. Earlier in her career, she held roles of increasing
responsibility in clinical pharmacology and clinical development at Ono
Pharmaceutical, AstraZeneca, and Sanofi. Ms. Kennedy holds a B.Sc. in
Biochemistry and Pharmacology from the University of Strathclyde.
Mr. Ramsay joined Outpost from The Medicines Company, which he joined
through the acquisition of Incline Therapeutics, where he was Senior
Vice President, Manufacturing and Supply Operations. Prior to Incline,
he was Senior Vice President, Manufacturing Operations at Cell Genesys
with responsibility for three GMP manufacturing facilities. Previously,
Mr. Ramsay served as Vice President, Transdermal Manufacturing at ALZA
Corporation. He has also held various positions with SEQUUS
Pharmaceuticals, including Vice President, Manufacturing Operations, as
well as various positions at Syntex Corporation focusing on
manufacturing, product development, and regulatory affairs. Mr. Ramsay
holds a Bachelor of Pharmacy degree from the University of Nottingham.
About Outpost Medicine
Outpost Medicine is a biopharmaceutical company focused on the
development of novel therapeutics for the treatment of urologic and
gynecologic disorders. Its lead product candidate, OP-233 (formerly
TAK-233), is currently in Phase I for the treatment of stress urinary
incontinence (SUI). SUI occurs when physical movement or activity, such
as coughing, sneezing, laughing, exercise, or heavy lifting puts
pressure (physical stress) on weakened urethral sphincter or pelvic
floor muscles resulting in unintentional loss of urine. SUI is distinct
from urge incontinence, also known as overactive bladder (OAB), which is
caused by involuntary contraction of bladder muscles. In the United
States alone, more than 18 million women are afflicted with SUI. There
are currently no medicines approved in the United States to treat this
condition, and approved agents in other parts of the world tend to be
poorly tolerated or have limited efficacy. Located in Boston and London,
Outpost is a private company launched in 2016 with a $41 million Series
A venture capital financing from Frazier Healthcare Partners, Adams
Street Partners, Novo A/S, and Vivo Capital. For more information, visit
Outpost’s website at www.outpostmedicine.com.
Contacts
Outpost Medicine
David Socks, +1-650-325-5156
